TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study

Overview

This study collects the clinical data of new-onset ocular myasthenia gravis (OMG) patients, assesses outcomes and adverse effects of different treatment options, and evaluate risk factors of conversion to generalized MG(GMG).

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 4, 2024

Detailed Description

This is a multicenter, observational cohort trial in the real-world clinical setting recruiting new-onset OMG patients from Neurology Departments of 7 hospitals in different regions of China. Clinical manifestations, laboratory test results, chest imaging and history of thymectomy are recorded. Treatment option are determined according to the physician's judgment and preferences of the patients. Patients are followed up prospectively on regular to assess the outcomes of treatments and monitor any side effects. Peripheral blood samples are collected annually. The investigators plan to recruit a final sample of 200 patients for analysis.

Interventions

  • Drug: Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)
    • Treatment regimens are determined according to the physician’s judgment and preferences of the patients.

Arms, Groups and Cohorts

  • Patients with autoimmune ocular MG
    • Newly-onset OMG patients who agreed to join the follow-up cohort

Clinical Trial Outcome Measures

Primary Measures

  • Conversion rate from ocular to generalized MG at the last follow-up visit.
    • Time Frame: 144 weeks
    • Ocular MG patients are followed up to determine the ratio of conversion to generalized disease at the end of follow-up. The clinical records will be retrospectively analyzed to search for risk factors of progressing.
  • Changes in the ratio of patients that achieve the level 2 of MG Status and Treatment Intensity, scale (MGSTI) or better.
    • Time Frame: Baseline, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks
    • Ocular MG patients are followed up to determine the ratio of patients that achieve the status of MGSTI 2 or better at each period piont of follow-up. The clinical records will be retrospectively analyzed to search for risk factors prolonged the regimens reduction.
  • Changes in proportion of patients with treatment-related adverse events.
    • Time Frame: Baseline, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks
    • Treatment-Related Adverse Events (AEs) are evaluated in patients receiving different treatment protocol
  • Change in Quantitative Myasthenia Gravis (QMG) Scores and Quantitative the Absolute and Relative Score of MG(ARS-MG) Scores from Baseline.
    • Time Frame: 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks
    • The improvement of clinic status of OMG patients was assessed by doctors according to QMG and ARS-MG score. The QMG is a 13-item scale which measures ocular, bulbar, limb function and respiratory function. The total score ranges from 0 (no myasthenic findings) to 39 (maximal myasthenic deficits) obtained by summing the responses to each individual item.The ARS-MG is a 8-item scale which has a more detailed measure to assess ocular function . The total score ranges from 0 (no myasthenic findings) to 60 (maximal myasthenic deficits) obtained by summing the responses to each individual item.
  • Change in MG-specific Activities of Daily Living scale(MG-ADL) score from Baseline.
    • Time Frame: 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks
    • The improvement of clinic status of OMG patients was assessed by patients themselves according to MG-ADL score. The The MG-ADL is an 8-item scale to assess symptoms of myasthenia gravis patients obtained by summing the responses to each individual item (Grades: 0,1,2,3). The score ranges from 0 to 24.

Secondary Measures

  • Changes in titers of MG antibodies.
    • Time Frame: Baseline, 48 weeks, 96 weeks, 144 weeks
    • MG antibodies are detected at enrollment and the titers of antibodies will be monitored annually.
  • Improvement of repeated frequency electrical stimulation tests (RNS) and single fiber electromyography (SFEMG).
    • Time Frame: 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks
    • RNS and SFEMG will be monitored on time to assess the clinic status.
  • Relapse rate during follow-up period.
    • Time Frame: Baseline, 144 weeks
    • Ocular MG patients are followed up to determine the relapse rate at the end of follow-up. The clinical records will be retrospectively analyzed to search for risk factors of recurrence.

Participating in This Clinical Trial

Inclusion Criteria

1. Age >18 years and<75 years;

2. Clinical Diagnosis of MG with supporting evidence:

Patients with ocular muscle type MG who have never received treatment meet one of the diagnoses (1) and (2)-(5): (1) The patient's symptoms involve the extraocular muscles, except for drooping eyelids and diplopia, no other clinical symptoms; (2) unequivocal clinical response to pyridostigmine; (3) positive acetylcholine receptor antibody or musk antibody; (4) decrement of more than 10% in repetitive nerve stimulations study (RNS); (5) the "trembling" of the single fiber electromyography (SFEMG) is broadened with or without blockade;

3. Willingness to sample collection, imaging study and other disease-related examinations and assessments;

4. The results of pregnancy tests for female subjects with fertility during the screening period should be negative and effective contraception was used by the patient and her spouse during the study period;

5. Patients with informed consent;

6. Predicted survival time is longer than 3 years.

Exclusion Criteria

1. History of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue;

2. Patients who may have other diseases that may lead to eyelid drooping, peripheral muscle weakness or diplopia;

3. Age ≤18 years or ≥75 years;

4. Patients who have been taking glucocorticoids or associated immunosuppressants due to other immune system diseases;

5. Patients who cannot use immunosuppressants due to other chronic diseases;

6. Patients who are unable to cooperate with follow-up and self-assessment due to severe mental illness or cognitive impairment;

7. Pregnant women, lactating women and patients with fertility plans during the trial;

8. Patients who have suffered from severe infections or malignant tumors in the last 1 month and are unable to receive immunosuppressants treatments;

9. Patients who are not willing to cooperate with repeated frequency electrical stimulation tests and chest CT examinations;

10. Patients who are not willing to participate in this study;

11. Patients who are unable to sign informed consent;

12. Predicted survival time is shorter than 3 years;

13. Patients who are not suitable to participated in the trial after researchers' assessment.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Tang-Du Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jun Guo, MD, Associate Professor – Tang-Du Hospital
  • Overall Official(s)
    • Jun Guo, Study Chair, Tangdu Hospital, Air Force Military Medical University
  • Overall Contact(s)
    • Jun Guo, M.D., 86-29-8477 8844, guojun_81@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.